CA2322493A1 - Nitrate salt of anti-ulcer medicine - Google Patents

Nitrate salt of anti-ulcer medicine Download PDF

Info

Publication number
CA2322493A1
CA2322493A1 CA002322493A CA2322493A CA2322493A1 CA 2322493 A1 CA2322493 A1 CA 2322493A1 CA 002322493 A CA002322493 A CA 002322493A CA 2322493 A CA2322493 A CA 2322493A CA 2322493 A1 CA2322493 A1 CA 2322493A1
Authority
CA
Canada
Prior art keywords
salt
free valence
nitrate
nitrate salts
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322493A
Other languages
English (en)
French (fr)
Inventor
Piero Del Soldato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2322493A1 publication Critical patent/CA2322493A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002322493A 1998-03-05 1999-02-25 Nitrate salt of anti-ulcer medicine Abandoned CA2322493A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI98A000442 1998-03-05
IT98MI000442A IT1299198B1 (it) 1998-03-05 1998-03-05 Sali nitrati di farmaci antiulcera
PCT/EP1999/001226 WO1999045004A1 (en) 1998-03-05 1999-02-25 Nitrate salt of anti-ulcer medicine

Publications (1)

Publication Number Publication Date
CA2322493A1 true CA2322493A1 (en) 1999-09-10

Family

ID=11379185

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322493A Abandoned CA2322493A1 (en) 1998-03-05 1999-02-25 Nitrate salt of anti-ulcer medicine

Country Status (19)

Country Link
US (1) US6503929B1 (https=)
EP (1) EP1068196B1 (https=)
JP (1) JP2002505328A (https=)
KR (1) KR20010041522A (https=)
CN (1) CN1249053C (https=)
AT (1) ATE273297T1 (https=)
AU (1) AU752919B2 (https=)
BR (1) BR9908428A (https=)
CA (1) CA2322493A1 (https=)
DE (1) DE69919341T2 (https=)
DK (1) DK1068196T3 (https=)
ES (1) ES2226357T3 (https=)
HU (1) HUP0100853A3 (https=)
IL (1) IL137721A0 (https=)
IT (1) IT1299198B1 (https=)
PT (1) PT1068196E (https=)
RU (1) RU2228331C2 (https=)
SI (1) SI1068196T1 (https=)
WO (1) WO1999045004A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
AU772188B2 (en) 1998-11-17 2004-04-08 Nitromed, Inc. Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
IT1317735B1 (it) * 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US7129161B2 (en) * 2001-07-19 2006-10-31 Trikon Holdings Limited Depositing a tantalum film
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003261281A1 (en) 2002-07-29 2004-02-16 Nicox S.A. Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2304967C2 (ru) * 2005-05-26 2007-08-27 Государственное общеобразовательное учреждение высшего профессионального образования Казанский государственный медицинский университет Способ лечения язвенной болезни желудка и двенадцатиперстной кишки

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1397436A (en) * 1972-09-05 1975-06-11 Smith Kline French Lab Heterocyclic n-cyanoguinidines
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4375547A (en) * 1980-10-02 1983-03-01 Eli Lilly And Company N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine
EP0224612A1 (de) 1985-12-05 1987-06-10 HEUMANN PHARMA GMBH & CO Verfahren zur Herstellung von N-Cyano-N'-methyl-N"[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidin
ES2053462T3 (es) * 1987-04-06 1994-08-01 Heumann Pharma Gmbh & Co Procedimiento para la produccion de derivados de nitroetano.
TW205041B (https=) * 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co

Also Published As

Publication number Publication date
HUP0100853A3 (en) 2003-01-28
JP2002505328A (ja) 2002-02-19
DE69919341T2 (de) 2005-09-08
HUP0100853A2 (hu) 2001-10-28
CN1291982A (zh) 2001-04-18
CN1249053C (zh) 2006-04-05
RU2228331C2 (ru) 2004-05-10
IL137721A0 (en) 2001-10-31
DK1068196T3 (da) 2004-11-29
AU752919B2 (en) 2002-10-03
PT1068196E (pt) 2004-10-29
ATE273297T1 (de) 2004-08-15
EP1068196A1 (en) 2001-01-17
WO1999045004A1 (en) 1999-09-10
SI1068196T1 (en) 2004-12-31
US6503929B1 (en) 2003-01-07
DE69919341D1 (de) 2004-09-16
ES2226357T3 (es) 2005-03-16
IT1299198B1 (it) 2000-02-29
EP1068196B1 (en) 2004-08-11
BR9908428A (pt) 2000-10-31
AU3030399A (en) 1999-09-20
ITMI980442A1 (it) 1999-09-05
KR20010041522A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
CA2322493A1 (en) Nitrate salt of anti-ulcer medicine
JP3510955B2 (ja) 改良された抗ウイルス化合物
CH630632A5 (de) Verfahren zur herstellung neuer cephalosporinderivate.
AU757155B2 (en) Pharmaceutical compositions for ulcer
WO2023116734A1 (en) Fused pyrrolidine compounds and compositions for treatment of respiratory viral infections
US4189479A (en) Cephalosporin esters
CA1102307A (en) 2-lower alkyl-7-substituted amino-2 or 3-cephem-4- carboxylic acid compounds and processes for preparation thereof
JPS60105672A (ja) 胃抗分泌剤としてのチアトリアジンジオキサイド類
US3822256A (en) Crystalline monohydrates of sodium and potassium cephalexin
US3840535A (en) Dimethanesulfonates of certain 7-(o-aminomethylphenylacetamido)-3-((heterocyclylthio)methyl)-ceph-3-em-4-carboxylic acids
GB1382494A (en) Acylaminocephalosporanic acids and process for their manufacture
JP2862912B2 (ja) 5’―(4―プロピルまたは4―イソプロピルピペラジニル)ベンゾキサジノリファマイシン誘導体
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
JPS61207331A (ja) 複素環式ジスルフイツド
US3326753A (en) Benzimidazole anthelmintic compositions and method of use
JPH05271239A (ja) セフェム化合物及び抗菌剤
JPH01199977A (ja) セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物
SU1052159A3 (ru) Способ получени производных 7-/2-(2-аминотиазолил)-2-оксииминоацетамидо/- 3-цефем-4-карбоновых кислот или их сложных эфиров или их фармацевтически приемлемых солей
DK158673B (da) Analogifremgangsmaade til fremstilling af cephalosporinforbindelser.
CA1117522A (en) Cephalosporin esters
WO2025174721A1 (en) Vps4 inhibitors
US4139703A (en) Indole cephalosporin derivatives
JPS62167726A (ja) ベンズイミダゾ−ル誘導体を含む医薬組成物
JPS5885895A (ja) セフアロスポリン誘導体および経口投与用細菌感染症治療剤
JPS6296456A (ja) アントラニル酸誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued